What Is 17-hydroxyprogesterone caproate

Overview

17-hydroxyprogesterone caproate (17-OHPC) is a synthetic progestin derivative of progesterone, developed to help prevent preterm birth in at-risk pregnancies. It was primarily prescribed to women with a history of prior spontaneous preterm delivery, a major risk factor for recurrence.

The drug works by mimicking the effects of natural progesterone, which helps maintain uterine quiescence and cervical integrity during pregnancy. Though initially hailed as a breakthrough, its long-term efficacy and safety have been debated following subsequent clinical trials and regulatory reviews.

• First FDA-approved use: In 2003, the FDA approved 17-OHPC under the brand name Makena for reducing preterm birth risk in women with a singleton pregnancy and prior preterm birth.
• Administration method: The drug is delivered via weekly intramuscular injections, typically starting between weeks 16 and 20 of gestation and continuing until week 37.
• Initial clinical trial results: A pivotal study published in 2003 showed a 33% relative reduction in births before 35 weeks among women receiving 17-OHPC compared to placebo.
• Manufacturer: Originally developed and marketed by K-V Pharmaceutical Company, later acquired by AMAG Pharmaceuticals, which increased the price dramatically.
• Regulatory controversy: In 2020, the FDA requested the withdrawal of Makena after confirmatory trials failed to demonstrate consistent efficacy, sparking debate among clinicians and patients.

How It Works

17-hydroxyprogesterone caproate functions by modulating hormonal pathways involved in maintaining pregnancy and preventing premature labor. Though its exact mechanism is not fully understood, it is believed to act through progesterone receptors in the uterus and cervix.

• Progestin Action:17-OHPC binds to progesterone receptors in uterine tissue, suppressing myometrial contractions and reducing inflammation, which may delay preterm labor onset.
• Cervical Stability: The drug may help maintain cervical length and prevent premature shortening, a known predictor of preterm birth, especially in high-risk women.
• Anti-inflammatory Effects: It exerts anti-inflammatory properties in the reproductive tract, potentially reducing cytokine-driven pathways that trigger early labor.
• Metabolism: After injection, 17-OHPC is slowly released and metabolized into 17-hydroxyprogesterone, which has a half-life of approximately 10–14 days.
• Dosing Schedule: Weekly injections ensure sustained therapeutic levels in the bloodstream, with peak concentrations reached within 24 to 48 hours post-injection.
• Fetal Exposure: While the drug crosses the placenta, no significant increase in congenital anomalies has been observed, though long-term neurodevelopmental studies remain limited.

Key Comparison

This comparison highlights how 17-OHPC differed from other progesterone forms in formulation, cost, and regulatory journey. While structurally similar to natural hormones, its synthetic caproate ester extended its release but also contributed to pricing and safety debates.

Key Facts

17-hydroxyprogesterone caproate has been the subject of extensive clinical, economic, and regulatory scrutiny over the past two decades. These key facts summarize its development, use, and impact on maternal healthcare.

• Approval year: The FDA granted approval in 2003 based on a single trial with 46% reduction in early preterm births before 32 weeks.
• Cost increase: After acquisition by AMAG, the price rose from $10 to over $1,500 per dose, prompting public and congressional backlash.
• Follow-up trial (2019): The PROLONG trial found no statistically significant reduction in preterm birth, leading to FDA’s 2020 withdrawal request.
• Patient access: Over 150,000 doses were administered annually in the U.S. at its peak usage before safety concerns emerged.
• Generic availability: In 2021, the FDA approved a generic version, reducing cost but not resolving efficacy debates.
• Long-term outcomes: A 2022 follow-up study found no significant difference in child development outcomes at age 2.5 years between exposed and unexposed groups.

Why It Matters

The story of 17-OHPC reflects broader challenges in drug approval, post-market surveillance, and healthcare economics. It underscores the tension between early promise and long-term evidence in maternal-fetal medicine.

• Regulatory precedent: Makena was one of the first drugs approved under accelerated FDA pathways based on surrogate endpoints, later requiring confirmatory trials.
• Patient advocacy: Many women continued to demand access despite FDA concerns, citing personal success stories and limited alternatives.
• Cost implications: The drug’s pricing model sparked debates about pharmaceutical ethics and insurance coverage for high-cost obstetric treatments.
• Clinical uncertainty: The discrepancy between initial and long-term trial results highlights the need for robust post-marketing studies in pregnancy.
• Future of preterm prevention: The Makena experience has shifted focus toward cervical length screening and personalized progesterone regimens.

While 17-OHPC is no longer widely recommended, its legacy continues to influence how new therapies for preterm birth are evaluated and regulated. The balance between innovation and evidence remains a central theme in maternal health.